ENSC
Ensysce Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 4
Revenue Plunges
EPS Below Expectations
Revenue Below Expectations
Revenue Keeps Dropping
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ENSC
Ensysce Biosciences, Inc.
A clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the fear of and the potential for misuse, abuse, and overdose
7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037
--
Ensysce Biosciences, Inc., was incorporated in Delaware in April 2003. The company is a clinical-stage biotechnology company that leverages its proprietary technology platform to develop safer prescription drugs. Using its trypsin-activated abuse protection and multidrug abuse resistance platform, the company is developing a new class of powerful, tamper-proof opioids that can prevent drug abuse and overdose. Ensysce's products are expected to provide a safer option to treat severe pain and help prevent deaths from opioid abuse, thereby reducing human and economic costs.
Company Financials
EPS
ENSC has released its 2024 Q4 earnings. EPS was reported at -2.90, versus the expected -1.95, missing expectations. The chart below visualizes how ENSC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ENSC has released its 2024 Q4 earnings report, with revenue of 1.30M, reflecting a YoY change of 153.12%, and net profit of -3.56M, showing a YoY change of -1.71%. The Sankey diagram below clearly presents ENSC’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
